Showing results (531-540 of 8,447) with videos related to
Sort By:
Pageof 845
Journal of Neuroimmunology|July 30, 1999
Multiple sclerosis--emerging concepts of disease pathogenesisJ AntelJournal of Neuroimmunology|July 30, 1999
Pathogenesis of tissue injury in MS lesionsB D Trapp, L Bö, S Mörk, et al.Journal of Neuroimmunology|February 16, 2000
Antibody directed against mannan of the Mycobacterium tuberculosis cell envelope provokes blood-brain barrier breakdownI J Namer, J SteibelJournal of Neuroimmunology|January 15, 2000
Immune deviation following stress odor exposure: role of endogenous opioidsJ A Moynihan, J D Karp, N Cohen, et al.Journal of Neuroimmunology|January 15, 2000
The central nervous system-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS)J F Kaye, N Kerlero de Rosbo, I Mendel, et al.Journal of Neuroimmunology|January 15, 2000
Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudineR H Enting, N A Foudraine, J M Lange, et al.Journal of Neuroimmunology|June 22, 1999
Early differentiation of thymic dendritic cells in the absence of glucocorticoidsR Sacedón, A Vicente, A Varas, et al.Journal of Neuroimmunology|June 22, 1999
Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravisD R Huang, R Pirskanen, G Matell, et al.Journal of Neuroimmunology|June 22, 1999
Involvement of catecholamines in recall of the conditioned NK cell responseC M Hsueh, J S Kuo, S F Chen, et al.Journal of Neuroimmunology|June 23, 1999
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupR A Rudick, D L Cookfair, N A Simonian, et al.Pageof 845